Home Applications 213036 Application 213036
Type NDA
Sponsor AMIVAS Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 ARTESUNATE ARTESUNATE POWDER;INTRAVENOUS 110MG/VIAL Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213036-001 ARTESUNATE ARTESUNATE 110MG/VIAL POWDER / INTRAVENOUS RLD, RS 2020-05-26
Orange Book patents# Current patent rows page 1 of 1 · 2 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N213036-001 12121506 2044-02-16 Drug product 2024-10-23 N213036-001 12390442 2044-02-16 U-4433 2026-03-23
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N213036-001 ODE-290 2027-05-26
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 41 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213036-001 ARTESUNATE 110MG/VIAL POWDER / INTRAVENOUS RLD, RS 2020-05-26 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213036-001 12390442 2044-02-16 U-4433 2026-03-23 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213036-001 12390442 2044-02-16 U-4433 2026-03-23 c2088c7a36db…2026-09-14 22:38:34 2026-08 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213036-001 12390442 2044-02-16 U-4433 2026-03-23 84e616aacf4f…2026-08-18 06:07:40 2026-07 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213036-001 12390442 2044-02-16 U-4433 2026-03-23 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 2680178bc6a6…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 d8e5a09893c0…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213036-001 12121506 2044-02-16 Drug product 2024-10-23 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213036-001 12390442 2044-02-16 U-4433 2026-03-23 a50c72e98297…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 76 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 7 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 73607-001 Artesunate Artesunate Amivas, LLC NDA Current 73607-001 Artesunate Artesunate Amivas, LLC NDA Current 73607-011 Artesunate Artesunate Amivas, LLC NDA Current 73607-011 Artesunate Artesunate Amivas, LLC NDA Current 73607-011 Artesunate Artesunate Amivas, LLC NDA Current 73607-011 Artesunate Artesunate Amivas, Inc NDA Current 73607-011 Artesunate Artesunate Amivas, Inc NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 85682 SUPPL 2026-04-15 80875 SUPPL 2025-01-21 80870 SUPPL 2025-01-17 74967 SUPPL 2023-08-01 74966 SUPPL 2023-08-01 73692 SUPPL 2023-03-06 73678 SUPPL 2023-03-06 70105 SUPPL 2022-02-07 70104 SUPPL 2022-02-07 63706 ORIG 2020-06-25 63309 ORIG 2020-05-27 63301 ORIG 2020-05-27